Fate FT839 Dual CD19/CD38 CAR-T Cleared

Company Fate Therapeutics, Inc. (Nasdaq: FATE) Event Type FDA clearance of Investigational New Drug (IND) application Modality Off-the-shelf, iPSC-derived allogeneic dual-CAR T cell — 13-point genetically edited, manufactured from a renewable master cell bank Targets CD19 and CD38 — dual antigen co-targeting Indication Phase 1/2…